On March 7th, the 13th Western Chengdu Laboratory Medicine and Blood Transfusion Products Exhibition was held in Chengdu Century City New International Convention and Exhibition Center. Ningbo Aocheng Biotechnology Co., Ltd. brought the newly developed fluorescence immunoassay technology platform and reagents to the exhibition. Winning the most important vision, bringing more possibilities for clinical diagnosis solutions.

Company Profile 

Ningbo Aocheng Biotechnology Co., Ltd. is a high-tech biological enterprise focusing on the early detection, diagnosis, prevention and monitoring of diseases. By providing reliable, fast and convenient in vitro diagnostic products, it can provide accurate test results for diagnosis and treatment. At present, the company's biomedical team continues to conduct in-depth exploration and prospective research in the field of high-risk diseases of pregnant women such as hypertension. We will be committed to providing professional clinical diagnosis solutions for women and children's health.

Technology platform

Aocheng independently develops three in vitro diagnostic technology platforms. In addition to the fluorescent immunoquantitative detection technology platform that has been unveiled at the exhibition, it will also launch a microfluidic fluorescent immunoquantitative detection technology platform and a magnetic particle acridine chemiluminescence detection technology platform. To meet the needs of different methodologies and different throughputs.